Articles related to MEDICARE

Explore the latest findings on endophthalmitis risks following glaucoma surgeries to optimize your postoperative care strategies.

The upcoming shift from HCC Version 24 to Version 28 poses serious implications for oncology practices, particularly in how they report patient complexity. A proactive approach is essential to navigate these sweeping changes effectively.

Discover how the 340B Drug Pricing Program influences prescription trends toward higher-cost biologics over biosimilars, and what this means for cost-effective healthcare.

New research underscores the dramatic increase in prior authorization for oral oncology drugs under Medicare Part D. Understand the implications for your practice as insurers tighten their grip on treatment decisions.

The HHS has initiated a landmark policy to negotiate drug prices under Medicare Part D. Be prepared for how these changes could affect your patients’ medication affordability starting in 2026.

Explore the complexities and challenges that could arise for oncologists with the potential expansion of blood biopsy insurance coverage through the MCED Screening Coverage Act.